NanoViricides, Inc. (NYSE American: NNVC) announced it has entered into a securities purchase agreement with a single fundamental institutional investor for a registered direct offering expected to generate approximately $3.8 million in gross proceeds. The offering involves the sale of 2,516,339 common shares, or pre-funded warrants in lieu thereof, along with warrants to purchase an equal number of common shares at an exercise price of $1.75 per share, expiring five and a half years after issuance. The transaction is expected to close on or about July 27, 2026, subject to customary conditions, with D. Boral Capital LLC serving as exclusive placement agent.
The capital raise comes as NanoViricides advances its lead drug candidate, NV-387, a broad-spectrum antiviral designed to treat respiratory infections including RSV, COVID-19, Long COVID, influenza, and other viral diseases such as MPOX, smallpox, and measles. The company is also developing NV-HHV-1 for shingles and two COVID-19 candidates: NV-CoV-2, which uses NV-387 alone, and NV-CoV-2-R, which encapsulates remdesivir in polymeric micelles. The company believes that NV-CoV-2-R, leveraging the FDA-approved remdesivir, could have a clearer path to approval if safety is comparable.
NanoViricides' platform technology is based on TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc. The company holds exclusive perpetual licenses for multiple antiviral indications, including HIV, hepatitis B and C, rabies, herpes, influenza, dengue, Ebola, and certain coronaviruses. The company plans to seek additional licenses for RSV, poxviruses, and enteroviruses pending initial research success.
The offering provides crucial funding as NanoViricides focuses on advancing NV-387 into Phase II human clinical trials. The company cautions that drug development is lengthy and capital-intensive, and there is no assurance that any candidates will prove effective or safe in human trials. For more details, the full press release is available at https://nnw.fm/2qH5W.
This financial move underscores the company's commitment to addressing significant unmet medical needs in antiviral therapy, particularly in the wake of the COVID-19 pandemic. The investment from a single institutional investor signals confidence in NanoViricides' technology and pipeline. As the company progresses, it will need to navigate regulatory hurdles and clinical trial outcomes, but the additional capital provides a runway for these critical steps.
Investors and stakeholders can find the latest updates on NanoViricides at https://nnw.fm/NNVC. The company's ability to execute its development plans will be closely watched as it aims to bring novel antiviral treatments to market.
